Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park(Dong-A University), David H. Kirn(Alameda Applied Sciences Corporation (United States)), Jae‐Seok Kim(Dong-A University), Manijeh Daneshmand(University of Ottawa), John C. Bell(Ottawa Hospital), Daniel Y. Sze(Stanford Medicine), Ta‐Chiang Liu(Washington University in St. Louis), Kelly Speth, Tae-Ho Hwang(Pusan National University), Sung Yong Oh(Korea University Medical Center), Chohee Park(Green Cross (South Korea)), Young‐joo Ahn(Green Cross (South Korea)), Jin-Han Yoon(Dong-A University), Herbert M. Pinedo(Leiden University), Sang‐Young Han(Dong-A University), Hyuk‐Chan Kwon(Dong-A University), Anne Moon(Geisinger Medical Center), Byung Geon Rhee(Green Cross (South Korea)), Sook Hee Hong(Dong-A University)
Cited by 522
Related Papers
Fluorouracil: biochemistry and pharmacology.
|Journal of Clinical Oncology|1988|834
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
|Proceedings of the National Academy of Sciences|1994|691
The drug resistance-related protein LRP is the human major vault protein
|Nature Medicine|1995|619
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
|JNCI Journal of the National Cancer Institute|2001|593
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
|Pharmacology & Therapeutics|1990|518